Product Name :
TML-6
Description:
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research.
CAS:
1462868-88-7
Molecular Weight:
523.62
Formula:
C30H37NO7
Chemical Name:
(5E)-6-(3,4-dimethoxyphenyl)-3-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]-N,N-diethyl-3-methyl-4-oxohex-5-enamide
Smiles :
CC(CC(=O)N(CC)CC)(C(=O)/C=C/C1=CC(OC)=C(C=C1)OC)C(=O)/C=C/C1=CC(OC)=C(C=C1)OC
InChiKey:
UWVCYNXVZRDWSD-UNZYHPAISA-N
InChi :
InChI=1S/C30H37NO7/c1-8-31(9-2)29(34)20-30(3,27(32)16-12-21-10-14-23(35-4)25(18-21)37-6)28(33)17-13-22-11-15-24(36-5)26(19-22)38-7/h10-19H,8-9,20H2,1-7H3/b16-12+,17-13+
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research.|Product information|CAS Number: 1462868-88-7|Molecular Weight: 523.62|Formula: C30H37NO7|Chemical Name: (5E)-6-(3,4-dimethoxyphenyl)-3-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]-N,N-diethyl-3-methyl-4-oxohex-5-enamide|Smiles: CC(CC(=O)N(CC)CC)(C(=O)/C=C/C1=CC(OC)=C(C=C1)OC)C(=O)/C=C/C1=CC(OC)=C(C=C1)OC|InChiKey: UWVCYNXVZRDWSD-UNZYHPAISA-N|InChi: InChI=1S/C30H37NO7/c1-8-31(9-2)29(34)20-30(3,27(32)16-12-21-10-14-23(35-4)25(18-21)37-6)28(33)17-13-22-11-15-24(36-5)26(19-22)38-7/h10-19H,8-9,20H2,1-7H3/b16-12+,17-13+|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 120 mg/mL (229.17 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.{{Domvanalimab} MedChemExpress|{Domvanalimab} Purity & Documentation|{Domvanalimab} In stock|{Domvanalimab} supplier|{Domvanalimab} Autophagy} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Zinc Pyrithione} site|{Zinc Pyrithione} Proton Pump|{Zinc Pyrithione} Purity & Documentation|{Zinc Pyrithione} Formula|{Zinc Pyrithione} custom synthesis|{Zinc Pyrithione} Epigenetics} |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TML-6 (0.PMID:32997846 65-5.24 µg/mL; for 24 h) reduces the protein expression levels of APP and phospho-NF-κB, and induces the protein expression level of ApoE. TML-6 inhibits the mTOR signaling pathway through the suppression of phospho-mTOR. TML-6 (0.31, 0.63, 2.5, 5, 10, 20 μM; 24 h) reveals no cytotoxicity in Huh-7 cells at concentrations below 5 μM and has an IC50 of 4.19 µg/mL (8 μM). TML-6 (1.05, 2.09, 3.14, 4.19 μg/mL; 24 h) reduces the production of Aβ40 and Aβ42 between 1.05, 2.09 and 3.14 μg/mL (equal to 2, 4 and 6 μM) in a dose-dependent manner in N2a/APPswe cell. TML-6 can exhibit transcriptional activation of the Nrf2 gene in a dose-dependent manner, with the highest activity at a concentration of 1.32 µg/mL.|In Vivo:|TML-6 (diet; 150 mg/kg/day; for four months) treatment results in significant improvement in learning, suppression of the microglial activation marker Iba-1, and reduction in Aβ in the brain. TML-6 (oral; 150 mg/kg) has a T1/2 of 1.27 hours, a Cmax of 35.9 ng/mL and an AUC of 177 ng•hr/mL.|Products are for research use only. Not for human use.|
